Researchers discover Ral GTPase pathway driving LDLR degradation in liver cells
The pathway degrades low-density lipoprotein receptors in response to dietary cholesterol, while its inhibition restored cholesterol clearance in preclinical tests.

Researchers have identified an intracellular signaling pathway regulated by Ral GTPases that controls the turnover of the low-density lipoprotein receptor (LDLR) in the liver, as reported by nature.com nature.com
nature.comnature.comOpen source ↗. Chronic intake of dietary cholesterol triggers this mechanism by elevating RAS activity, which activates Ral proteins and drives the degradation of LDLR instead of allowing it to recycle back to the cell surface
nature.com
nature.comnature.comOpen source ↗. This regulatory circuit operates independently of transcriptional control and the PCSK9 protein
nature.com
nature.comnature.comOpen source ↗.
Molecular cascade and receptor routing
The activation of Ral proteins recruits the endocytic RalBP1–REPS1 complex, which directs LDLR from the cell membrane into lysosomes nature.com
nature.comnature.comOpen source ↗. Within these organelles, the receptor is degraded by the lysosomal protease cathepsin A (CTSA)
nature.com
nature.comnature.comOpen source ↗. Simultaneously, Ral activation diverts CTSA toward lysosomes for maturation and reduces its extracellular secretion, accelerating LDLR breakdown
nature.com
nature.comnature.comOpen source ↗.
Experimental activation of this pathway in hepatocytes—achieved through the deletion of RalGAPB or the overexpression of constitutively active Ral mutants—lowered LDLR levels and disrupted cholesterol clearance nature.com
nature.comnature.comOpen source ↗. Furthermore, analysis of human genetic data revealed that variants in this pathway correlate with altered circulating cholesterol levels
nature.com
nature.comnature.comOpen source ↗.
Pharmacological inhibition
To test whether the receptor destruction could be halted, researchers targeted CTSA activity in preclinical models nature.com
nature.comnature.comOpen source ↗. Pharmacological inhibition of CTSA restored hepatic LDLR function and enhanced blood cholesterol clearance
nature.com
nature.comnature.comOpen source ↗. The authors suggest that targeting components of this pathway represents a candidate therapeutic strategy for hypercholesterolaemia and associated cardiovascular disease
nature.com
nature.comnature.comOpen source ↗.



